Debevoise & Plimpton LLP

Debevoise & Plimpton LLP is equally adept at advising life sciences clients on FDA regulations governing drugs and medical devices as it is assisting major private equity investors with acquisitions in the sector. The practice offers litigation services in relation to price fixing allegations and matters tied to the opioid epidemic. Andrew Bab, Jennifer Chu and Kevin Rinker handle the firm’s transactional workload, advising on the structuring of acquisitions and assisting with licensing issues. Mark Goodman represents clients in civil litigation and white collar trials, while also advising on internal investigations, with Maura Monaghan taking the lead on product liability and mass tort litigation. In Washington DC, Paul Rubin handles FDA matters, including compliance and regulatory enforcement, and is also recommended for carrying out due diligence processes for private equity houses. All lawyers are New York-based unless otherwise specified.